Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 23, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/24/17 - "Fast Acting Orally Disintegrating Film" in Patent Application Approval Process (USPTO 20170056374)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lee, Catherine; Wang, Chien-Chiao, filed on November 14, 2016, was made available online on March 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to TAHO Pharmaceuticals Ltd.
3/24/17 - "New England Journal of Medicine" publishes long-term results of Gleevec for patients with chronic myeloid leukemia
By a News Reporter-Staff News Editor at Drug Week- In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec *, as an oral therapy for patients with chronic myeloid leukemia, or CML. According to the HYPERLINK " https://www.cancer.gov/research/progress/discovery/gleevec"\ nNational
3/24/17 - AARP: Repealing Obamacare would hurt Hawaii's seniors
AARP, a nonprofit, nonpartisan, social welfare organization, released a scathing assessment of the Republican-proposed health care bill that's facing opposition from not only Democrats but a segment of the GOP in the U.S. House of Representatives. AARP is strongly against the age tax and other aspects of the bill that will give tax breaks to drug c
3/24/17 - Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017
By a News Reporter-Staff News Editor at Drug Week Aeterna Zentaris Inc. will announce its fourth quarter and full-year 2016 financial and operating results after market close on Wednesday, March 15, 2017. The Company will host a conference call and webcast to discuss these results on Thursday, March 16, 2017 at 8:30 a.m. Eastern Time. About Aeter
3/24/17 - Agilent Technologies Extends Biopharma Portfolio with Advanced Mass Spec System
By a News Reporter-Staff News Editor at Drug Week Agilent Technologies Inc. introduces the latest addition to its portfolio of solutions for biopharmaceutical labs: the Agilent 6545 XT AdvanceBio LC/Q-TOF MS System. "Agilent is committed to providing complete workflow solutions to the biopharma industry that address critical areas for biotherape
3/24/17 - Alcon receives US FDA approval for new AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction [Kabulpress.org]
-The unique optical design of the ACTIVEFOCUS (TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses. Basel, March 23, 2017- Alcon, the global leader in eye care and a division of Novartis, has received approval from the US Food and Drug Administration f
3/24/17 - Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor [Sudan Tribune]
Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen. Ann Marie Navar, assistant professor of medicine at the Duke Clinical Research Institute and lead study investigator. Of a total 45,029 PCSK9 inhibitor prescription claims includ
3/24/17 - Amring Pharmaceuticals Acquired Six ANDAs
By a News Reporter-Staff News Editor at Drug Week Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced that it acquired six ANDAs from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc. Acquired ANDAs include niche otic and ophthalmic...
3/24/17 - Analyst Activity Aegis Reiterates Buy on Akebia Therapeutics (NASDAQ:AKBA)
Analyst Ratings For Akebia Therapeutics (NASDAQ:AKBA) Today, Aegis reiterated its Buy rating on Akebia Therapeutics (NASDAQ:AKBA). There are 1 hold rating, 6 buy ratings on the stock. The current consensus rating on Akebia Therapeutics (NASDAQ:AKBA) is Buy (Score: 2.86) with a consensus target price of $16.33 per share, a potential 79.49% upside. S
3/24/17 - Analyst Activity Jefferies Group LLC Reiterates Buy on Eiger Biopharmaceuticals (NASDAQ:EIGR)
Analyst Ratings For Eiger Biopharmaceuticals (NASDAQ:EIGR) Today, Jefferies Group LLC reiterated its Buy rating on Eiger Biopharmaceuticals (NASDAQ:EIGR). There are 4 buy ratings on the stock. The current consensus rating on Eiger Biopharmaceuticals (NASDAQ:EIGR) is Buy (Score: 3.00) with a consensus target price of $34.00 per share, a potential 22
3/24/17 - Analyst Activity Maxim Group Reiterates Buy on Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
Analyst Ratings For Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Today, Maxim Group reiterated its Buy rating on Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) with a price target of $9.00. There are 4 buy ratings on the stock. The current consensus rating on Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) is Buy (Score: 3.00) with a consensus target price of $14.2
3/24/17 - Analyst Activity Piper Jaffray Companies Initiates Coverage On Zosano Pharma Corp (NASDAQ:ZSAN) With a Overweight
Analyst Ratings For Zosano Pharma Corp (NASDAQ:ZSAN) Today, Piper Jaffray Companies initiated coverage on Zosano Pharma Corp (NASDAQ:ZSAN) with a Overweight. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Zosano Pharma Corp (NASDAQ:ZSAN) is Buy (Score: 2.67) with a consensus target price of $3.00 per share, a [
3/24/17 - Analyst Activity Piper Jaffray Companies Lowers Its Price Target On Horizon Pharma PLC (NASDAQ:HZNP) to
Analyst Ratings For Horizon Pharma PLC (NASDAQ:HZNP) Today, Piper Jaffray Companies lowered its price target on Horizon Pharma PLC (NASDAQ:HZNP) to per share. There are 1 hold rating, 10 buy ratings on the stock. The current consensus rating on Horizon Pharma PLC (NASDAQ:HZNP) is Buy (Score: 2.91) with a consensus target price of $28.91 per [?] T
3/24/17 - Analyst Activity Piper Jaffray Companies Raises Its Price Target On CymaBay Therapeutics (NASDAQ:CBAY) to
Analyst Ratings For CymaBay Therapeutics (NASDAQ:CBAY) Today, Piper Jaffray Companies raised its price target on CymaBay Therapeutics (NASDAQ:CBAY) to per share. There are 2 buy ratings on the stock. The current consensus rating on CymaBay Therapeutics (NASDAQ:CBAY) is Buy (Score: 3.00) with a consensus target price of $6.25 per share, a potential
3/24/17 - Analyst Activity Wedbush Raises Its Price Target On Ascendis Pharma A/S (NASDAQ:ASND) to
Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Wedbush raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to per share. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy (Score: 2.67) with a consensus target price of $30.67 per share, a [?] The pos
3/24/17 - Analyst Activity Wedbush Raises Its Price Target On Ascendis Pharma A/S (NASDAQ:ASND) to $34.00
Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Wedbush raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to $34.00 per share. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy (Score: 2.67) with a consensus target price of $30.67 per share, [?] Th
3/24/17 - App launched for Nairobi patients to get cheaper, genuine medicine [Mehr News Agency (Iran)]
Kenya was chosen as the destination for the launch due to internet penetration and the adoption of mobile technology in day-to-day life. This is not a problem that is unique to Kenya alone. We could have launched in Asia or Europe but Kenya was the ideal places launch it, Wood added.
3/24/17 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report (Mar. 6, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on March 6, 2017. The SEC file number is 0001171843-17-001299.. A U.S. Securities and Exchange Commission filing is a formal
3/24/17 - Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
3/24/17 - Argenx and Broteio Pharma partner to develop antibody for autoimmune diseases [Sudan Tribune]
Netherlands- based biotechnology company argenx and Broteio Pharma, a joint venture between Prothix and Bioceros, have agreed to partner for the development of a therapeutic antibody for severe autoimmune diseases. The antibody will be developed against a novel target in the complement cascade with therapeutic potential in auto-antibody-mediated an
3/24/17 - Avita Medical to Present at Needham Healthcare Conference
VALENCIA, Calif.& PERTH, Australia& LONDON Avita Medical Limited, a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita s Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April 2017. The presentation will take place at 9:20am ET
3/24/17 - Beat market volatility with these stock option trade ideas for Citigroup, Exelixis, Gilead Sciences, Tesla Motors, and US Oil Fund!
By a News Reporter-Staff News Editor at Drug Week- InvestorsObserver issues critical PriceWatch Alerts for C, EXEL, GILD, TSLA, and USO. Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. Tesla Inc, formerly Tesla Motors Inc designs, develops,.
3/24/17 - Bharat Book Bureau: Global Transdermal Patch Market
"Global Transdermal Patch Market& Clinical Pipeline Outlook 2022" report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
3/24/17 - Bharat Book Bureau: Infectious Disease Drugs: The Chinese Market
The Chinese infectious disease drug market is big, fast-growing and dominated by brands from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions that look for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehe
3/24/17 - Biogaran takes over Swipha's activities in Nigeria to produce quality generic medicines for the local market
LAGOS, Nigeria Biogaran, a French pharmaceutical company specialized in generic and biosimilar medicines, and a subsidiary of Servier, today announced the takeover of all the activities of Swipha, a Nigerian company that manufactures and distributes pharmaceutical products known for their quality. This is an important step forward in the...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415